CN117017921B - 一种人参皂苷脂质体及其制备方法 - Google Patents
一种人参皂苷脂质体及其制备方法 Download PDFInfo
- Publication number
- CN117017921B CN117017921B CN202311290337.6A CN202311290337A CN117017921B CN 117017921 B CN117017921 B CN 117017921B CN 202311290337 A CN202311290337 A CN 202311290337A CN 117017921 B CN117017921 B CN 117017921B
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- liposome
- parts
- cholesterol
- soybean lecithin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930182494 ginsenoside Natural products 0.000 title claims abstract description 186
- 229940089161 ginsenoside Drugs 0.000 title claims abstract description 186
- 239000002502 liposome Substances 0.000 title claims abstract description 134
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 72
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 36
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 36
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 36
- 239000000463 material Substances 0.000 claims abstract description 22
- 239000008280 blood Substances 0.000 claims abstract description 20
- 210000004369 blood Anatomy 0.000 claims abstract description 20
- 239000000243 solution Substances 0.000 claims abstract description 20
- 239000002245 particle Substances 0.000 claims abstract description 18
- 238000002390 rotary evaporation Methods 0.000 claims abstract description 18
- 230000036571 hydration Effects 0.000 claims abstract description 16
- 238000006703 hydration reaction Methods 0.000 claims abstract description 16
- 238000005303 weighing Methods 0.000 claims abstract description 15
- 239000007787 solid Substances 0.000 claims abstract description 14
- 239000011162 core material Substances 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 12
- 238000009210 therapy by ultrasound Methods 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 230000001603 reducing effect Effects 0.000 claims abstract description 10
- 239000008055 phosphate buffer solution Substances 0.000 claims abstract description 9
- 239000003960 organic solvent Substances 0.000 claims abstract description 8
- 239000005457 ice water Substances 0.000 claims abstract description 5
- 239000012528 membrane Substances 0.000 claims abstract description 5
- 239000000725 suspension Substances 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 238000005538 encapsulation Methods 0.000 claims description 16
- 241000208340 Araliaceae Species 0.000 claims description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 13
- 235000008434 ginseng Nutrition 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 4
- 238000001704 evaporation Methods 0.000 abstract description 4
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 24
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 24
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 21
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 19
- 150000003254 radicals Chemical class 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000007939 sustained release tablet Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- -1 peroxy radicals Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000013582 standard series solution Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311290337.6A CN117017921B (zh) | 2023-10-08 | 2023-10-08 | 一种人参皂苷脂质体及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311290337.6A CN117017921B (zh) | 2023-10-08 | 2023-10-08 | 一种人参皂苷脂质体及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117017921A CN117017921A (zh) | 2023-11-10 |
CN117017921B true CN117017921B (zh) | 2024-03-15 |
Family
ID=88635834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311290337.6A Active CN117017921B (zh) | 2023-10-08 | 2023-10-08 | 一种人参皂苷脂质体及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117017921B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103417479A (zh) * | 2012-05-16 | 2013-12-04 | 吉林大学 | 一种人参皂苷Rg3脂质体及其制备方法 |
CN104610410A (zh) * | 2015-01-05 | 2015-05-13 | 贵州信邦制药股份有限公司 | 一种人参皂苷Rd的提取工艺 |
CN105708801A (zh) * | 2016-02-04 | 2016-06-29 | 大连民族大学 | 一种20(R)-人参皂苷Rg3/大豆卵磷脂/胆固醇/叶酸脂质体药物制备方法和应用 |
CN106511274A (zh) * | 2016-11-28 | 2017-03-22 | 南昌大学 | 一种人参皂苷Rh2酯脂质体及制备方法和应用 |
CN112754994A (zh) * | 2019-11-05 | 2021-05-07 | 泰州医药城国科化物生物医药科技有限公司 | 一种人参皂苷脂质体及其制备方法 |
CN114748425A (zh) * | 2022-05-27 | 2022-07-15 | 江苏大学 | 一种人参皂苷Rb1脂质体及其制备方法 |
CN116459234A (zh) * | 2023-05-16 | 2023-07-21 | 烟台大学 | 一种靶向型人参皂苷Rg3递送制剂及其制备方法和应用 |
-
2023
- 2023-10-08 CN CN202311290337.6A patent/CN117017921B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103417479A (zh) * | 2012-05-16 | 2013-12-04 | 吉林大学 | 一种人参皂苷Rg3脂质体及其制备方法 |
CN104610410A (zh) * | 2015-01-05 | 2015-05-13 | 贵州信邦制药股份有限公司 | 一种人参皂苷Rd的提取工艺 |
CN105708801A (zh) * | 2016-02-04 | 2016-06-29 | 大连民族大学 | 一种20(R)-人参皂苷Rg3/大豆卵磷脂/胆固醇/叶酸脂质体药物制备方法和应用 |
CN106511274A (zh) * | 2016-11-28 | 2017-03-22 | 南昌大学 | 一种人参皂苷Rh2酯脂质体及制备方法和应用 |
CN112754994A (zh) * | 2019-11-05 | 2021-05-07 | 泰州医药城国科化物生物医药科技有限公司 | 一种人参皂苷脂质体及其制备方法 |
CN114748425A (zh) * | 2022-05-27 | 2022-07-15 | 江苏大学 | 一种人参皂苷Rb1脂质体及其制备方法 |
CN116459234A (zh) * | 2023-05-16 | 2023-07-21 | 烟台大学 | 一种靶向型人参皂苷Rg3递送制剂及其制备方法和应用 |
Non-Patent Citations (4)
Title |
---|
人参皂苷Rg_1脂质体制备工艺的优化;王亮;顾宜;费燕;;中国中药杂志(第23期);85-87 * |
人参皂苷Rg1脂质体的制备及稳定性研究;梁平;张旋;吴琳;张志红;王殿华;;昆明医学院学报(第01期);全文 * |
人参皂苷Rg3脂质体的处方优化及制备工艺研究;潘翠珊;王风华;翁艺芳;王岩;;中药新药与临床药理(第01期);全文 * |
甘草次酸修饰的人参皂苷Rh_2脂质体的制备及其体外评价;王琳;杨智钧;向敏;吴纪凯;方晨;;中国实验方剂学杂志(第05期);29-32 * |
Also Published As
Publication number | Publication date |
---|---|
CN117017921A (zh) | 2023-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10086032B2 (en) | Method for preparing a Camellia nitidissima Chi lipid-lowering and hypoglycemic agent | |
WO2013139111A1 (zh) | 黄蜀葵花总黄酮提取物及其制备方法 | |
CN104586775B (zh) | 一种治疗放射性肺炎的黄芪多糖缓释微球及其制备方法 | |
US20170028007A1 (en) | Solid dispersion containing desmodium styracifolium (osb.) merr. flavonoids, method of preparing same, and use thereof | |
KR20160064966A (ko) | 화학요법제 보조에 사용하는 의약 조성물 및 그 용도 | |
CN103585113A (zh) | 一种芹菜素聚乳酸缓释微球及其制备方法 | |
CN104055947B (zh) | 一种含有葡萄提取物的中药组合物及制备方法 | |
CN117017921B (zh) | 一种人参皂苷脂质体及其制备方法 | |
CN106579450B (zh) | 一种绞股蓝种子脂肪酸微胶囊及其制备方法和应用 | |
CN103566282B (zh) | 一种抗肿瘤作用中药组合物及制备方法 | |
CN101653580B (zh) | 一种治疗胃病的药物及其制备方法 | |
JP2021512997A (ja) | 分離された防風多糖及びその用途 | |
CN101249063B (zh) | 肝素钙/钠盐纳米口服制剂及其制备工艺 | |
CN104352427A (zh) | 一种含有穿心莲内酯的药物组合物及其用途 | |
CN103432124B (zh) | 氧化苦参碱在制备防治糖尿病肾病药物中的应用 | |
CN108379308B (zh) | 一种稳定的诃子速溶粉,其制备方法及应用 | |
CN102641342A (zh) | 一种治疗肾病的中药提取物和制备方法 | |
CN107802629B (zh) | 一种药物组合物在制备动脉粥样硬化治疗药物中的用途 | |
CN110339169A (zh) | 包覆维生素d和维生素k的纳米囊泡制剂及其应用 | |
CN111110825A (zh) | 一种降高尿酸的组合物及其制备方法和应用 | |
CN108273042A (zh) | 一种人参皂苷-胰岛素纳米凝胶及其制备方法与应用 | |
CN110638996B (zh) | 一种促进胰岛再生降糖复合物及其制备方法和用途 | |
Xu et al. | Clematis chinensis extract protects against diabetic nephropathy in rats | |
TWI387461B (zh) | 野薑花(hedychium coronarium koenig)地上部份於降低血糖之用途;野薑花地上部份之萃取物及組合物與其用途 | |
CN108379582B (zh) | 一种地塞米松磁性微球的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Junmei Inventor after: Li Qinyang Inventor after: Wang Minghui Inventor after: Pan Pengyuan Inventor after: Li Zhuowei Inventor after: Liu Zheng Inventor after: Jiang Xintong Inventor after: Jin Zheshun Inventor after: Pan Rong Inventor after: Yuan Mengjia Inventor before: Liu Junmei Inventor before: Li Qinyang Inventor before: Wang Minghui Inventor before: Pan Pengyuan Inventor before: Li Zhuowei Inventor before: Liu Zheng Inventor before: Jiang Xintong Inventor before: Jin Zheshun Inventor before: Pan Rong Inventor before: Yuan Mengjia |
|
GR01 | Patent grant | ||
GR01 | Patent grant |